TCTMD

TMD is a leading online platform dedicated to interventional cardiology, offering extensive insights into the percutaneous management of heart conditions. Since its debut at TCT 2000, TCTMD has been a valuable resource for healthcare providers and industry stakeholders, providing updates on the fast-changing landscape of cardiovascular medicine. Users can access news and information from global conferences, along with the latest advancements in devices and medications that are essential in everyday cardiology practice. TCTMD is managed by the Cardiovascular Research Foundation (CRF), which is committed to enhancing the quality of life for individuals with cardiovascular issues. CRF aims to promote the development and application of safe, effective, and minimally invasive treatments for heart disease. For further details, please visit our website at http://www.crf.org.

National, Trade/B2B

English, Spanish

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#303367

United States

#131864

Health/Medicine

#1090

Traffic sources

Monthly visitors

Articles

Simple, Phone-Based Strategy Improves BP Control in Stroke Survivors

4 days ago | tctmd.com | Todd Neale

News Conference News ESOC 2025 The intervention, tested out in Ghana, is unique as it relies on basic mobile phones, not smartphones. HELSINKI, Finland—In Ghana, survivors of a recent stroke who had hypertension experienced significant improvements in blood pressure control with a simple, mobile-health (mHealth) intervention led by nurses, according to the results of the PINGS-2 trial.
‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

1 week ago | tctmd.com | Michael O'Riordan

News Conference News EuroPCR 2025 The findings hint at why the AβYSS trial failed to show it was safe to stop beta-blockers after an MI in stable patients. PARIS, France—Patients with myocardial infarction and preserved LVEF who stop their beta-blocker have significant rises in heart rate and blood pressure that appear to increase the likelihood of adverse outcomes, particularly among those with hypertension, an analysis of the AΒYSS trial shows.
High Residual Risk of Recurrent Stroke Seen in AF Patients on Anticoagulants

1 week ago | tctmd.com | Todd Neale

News Conference News ESOC 2025 The findings highlight the need to both ensure adherence to anticoagulation and control other risk factors. HELSINKI, Finland—Patients with atrial fibrillation (AF) who have had an ischemic stroke continue to have a high risk of recurrent stroke even when they’re treated with oral anticoagulation, a systematic review and meta-analysis shows.
Early Coronary Function Testing Improves Quality of Life in ANOCA

1 week ago | tctmd.com | Yael L. Maxwell

News Conference News EuroPCR 2025 In the ILIAS ANOCA trial, using CFT to guide treatment according to ANOCA endotype led to larger QoL gains over 6 months.
Less Intense Checks May Be OK After IV Thrombolysis for Stroke: OPTIMISTmain

1 week ago | tctmd.com | Todd Neale

News Conference News ESOC 2025 Pulling back on the level of monitoring could improve nursing workflows and reduce resource use. HELSINKI, Finland—It may be possible to safely cut back on the level of monitoring performed in select patients with acute ischemic stroke treated with IV thrombolysis, results of the OPTIMISTmain trial suggest.
Tendyne Approved in US for High-risk Patients With Mitral Valve Disease

1 week ago | tctmd.com | Michael O'Riordan

The approval is tightly defined: the system will be for patients ineligible for surgery and with anatomy unfavorable for TEER. The US Food and Drug Administration has approved the Tendyne transcatheter mitral valve replacement (TMVR) system for the treatment of patients with mitral valve dysfunction, device manufacturer Abbott announced today.
Underexpanded Acurate neo2 Valves Tied to Worse Outcomes: ACURATE IDE

1 week ago | tctmd.com | Michael O'Riordan

News Daily News EuroPCR 2025 This factor helps explain why the device failed to match other commercially approved devices in the IDE trial. PARIS, France—More than one in five Acurate neo2 transcatheter heart valves (Boston Scientific) implanted in patients as part of the ACURATE investigational device exemption (IDE) study were underexpanded, a new analysis shows. In these cases, patients fared significantly worse compared with those with a fully opened valve.
ASSET-IT: Tirofiban Boosts Outcomes After IV Thrombolysis for Acute Stroke

1 week ago | tctmd.com | Todd Neale

News Conference News ESOC 2025 Citing a low hemorrhage rate and other issues, one expert says the results should be replicated before changing practice. HELSINKI, Finland—Adding IV tirofiban improves functional outcomes among patients undergoing systemic thrombolysis for acute ischemic stroke within 4.5 hours of symptom onset, results from the randomized ASSET-IT trial indicate.
What’s the Damage With Long COVID? Advanced Imaging Reveals Clues

1 week ago | tctmd.com | Caitlin Cox

Researchers used PET/MRI to detect otherwise invisible inflammation. Less clear is how this might influence patient care. Many patients referred for specialty care to address long-COVID symptoms have subtle evidence of inflammation and other cardiopulmonary abnormalities that can be detected with advanced imaging, a single-center study shows.
Don’t Forget to Floss! Better Oral Hygiene May Help Stave Off Stroke

2 weeks ago | tctmd.com | Todd Neale

News Conference News ESOC 2025 Oral hygiene is often neglected when it comes to stroke, but it’s low-hanging fruit than can aid in primary prevention. HELSINKI, Finland—People who report taking better care of their teeth, particularly with flossing, appear to have a lower risk of stroke over the long term, according to an analysis of the Atherosclerosis Risk in Communities (ARIC) study.